HALO Hits 52-Week High in Advancing Stage 2 Uptrend

HALO is trading at a fresh 52-week high of $85.76, firmly in a Stage 2 advancing trend with price above a rising 30-week MA. The market is focused on the stock’s strong uptrend, as it passes 7 of 8 trend template checks, with only the RS line lagging slightly. Overall sentiment is bullish, with an offensive setup in place despite the lack of a formal base or VCP pattern.

Technical Analysis

As of 2026-08-06 · Close $85.76

Stage Analysis

Stage 2 (Advancing) — Price holding above a rising 30-week MA — uptrend intact
(30-week MA 6-week slope: 3.04%)

Detected Patterns — What the Market Is Watching

• No actionable pattern detected at this time.

Minervini Trend Template — 7/8 Criteria Passed

Criterion	Status
Price > 150MA & 200MA	✅ Pass
150MA > 200MA	✅ Pass
200MA trending up (>=1 month)	✅ Pass
50MA > 150MA & 200MA	✅ Pass
Price > 50MA	✅ Pass
Price >= 30% above 52wk low	✅ Pass
Price within 25% of 52wk high	✅ Pass
RS Line at/near 3-month high	❌ Fail

Price is 0.0% off its 52-week high and 39.2% above its 52-week low.

Pattern Sentiment

Bullish — offensive setup in place (composite score: 5)

Halozyme Therapeutics, Inc. (HALO) — Institutional Research Report

Date: August 7, 2026 | Sector: Healthcare / Biotechnology | Industry: Biotechnology | Market Cap: $10.17B | Price: ~$85.75 (implied)

---

Company Overview & Business Model

Halozyme Therapeutics is a biopharmaceutical company built around its proprietary ENHANZE® drug delivery technology, based on recombinant human hyaluronidase (rHuPH20). This enzyme temporarily breaks down hyaluronan in the subcutaneous space, allowing large-volume biologic drugs (typically administered intravenously) to be delivered subcutaneously. The company monetizes this platform through a royalty-based partnership model, licensing its technology to major pharmaceutical partners while retaining rights to its own commercial products.

Revenue Streams (FY2025: $1.397B total revenue)

Revenue Stream	Description	Approx. % of Revenue (FY2025 est.)
**Royalties**	Earned on partner sales of ENHANZE-enabled products (e.g., DARZALEX SC, Phesgo, Ocrevus SC, Tecentriq SC, Herceptin Hylecta, HYQVIA)	~70–75%
**Product Sales**	XYOSTED (testosterone replacement), Hylenex recombinant	~5–8%
**Milestone & License Fees**	Upfront and milestone payments from new and existing partnerships	~15–20%

Key Growth Drivers:
– DARZALEX SC (Janssen/J&J): The largest royalty contributor; growing with multiple myeloma market expansion and earlier-line adoption.
– Phesgo (Roche): Fixed-dose combination of pertuzumab + trastuzumab for HER2+ breast cancer; strong uptake in adjuvant setting.
– Ocrevus SC (Roche): Recently launched subcutaneous formulation of the blockbuster MS drug; significant expansion opportunity.
– Tecentriq SC (Roche): Subcutaneous atezolizumab; launched in Europe and Japan, US approval expected.

Geographic Exposure (FY2025 est.): US ~50%, Europe ~35%, Japan/ROW ~15%.

---

Partnership Portfolio & Supply Chain

Halozyme operates a capital-light partnership model — manufacturing and commercialization are handled by partners, while Halozyme supplies the proprietary enzyme and technology.

Partner	Products	Status
**Janssen (J&J)**	DARZALEX SC (daratumumab)	Launched; major royalty driver
**Roche**	Phesgo, Ocrevus SC, Tecentriq SC, Herceptin Hylecta, Mabthera SC	Launched; multiple growth assets
**Takeda**	HYQVIA (immunoglobulin SC)	Launched; steady contributor
**Pfizer**	XYOSTED (commercial product)	Launched; direct product revenue
**AbbVie**	Subcutaneous anti-TNF (Humira biosimilar)	In development
**Eli Lilly**	Subcutaneous formulations (e.g., tirzepatide)	In development; potential major catalyst
**Bristol Myers Squibb**	Subcutaneous nivolumab/relatlimab	In development
**argenx**	ARGX-113 (efgartigimod SC)	Launched (VYVGART Hytrulo)
**ViiV Healthcare**	Cabotegravir SC (HIV)	Launched (Cabenuva)
**Chugai**	Various SC biologics	Launched (Japan)
**Acumen, Merus, Skye Bioscience**	Early-stage partnerships	Preclinical/Phase 1

Customer Concentration Risk: The top two partners (Janssen and Roche) likely account for >60% of total royalties (estimate). This concentration is a key risk factor.

---

Financial Statement Analysis

Income Statement — 5-Year Historical & 2-Year Estimates

Metric ($M)	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026E	FY2027E
**Total Revenue**	—	$660.1	$829.3	$1,015.3	$1,396.6	$1,750–1,850	$2,100–2,250
**Revenue Growth %**	—	—	25.6%	22.4%	37.6%	~28–32%	~20–25%
**Gross Profit**	—	$520.8	$636.9	$855.9	$1,167.8	—	—
**Gross Margin %**	—	78.9%	76.8%	84.3%	83.6%	~84–85%	~85%
**Operating Income**	—	$267.5	$337.6	$551.5	$802.6	—	—
**Operating Margin %**	—	40.5%	40.7%	54.3%	57.5%	~58–60%	~60%
**Net Income**	—	$202.1	$281.6	$444.1	$316.9	—	—
**Diluted EPS**	—	$1.44	$2.10	$3.43	$2.56	$4.20–4.50	$5.20–5.60
**Normalized EPS (ex-items)**	—	~$1.45	~$1.92	~$3.29	~$4.30	—	—

Note: FY2025 GAAP net income includes a ~$318M non-cash charge (restructuring/M&A related). Normalized income was $532.4M.

Valuation Metrics (as of 2026-08-07):
– Trailing P/E: 30.1x (GAAP)
– Forward P/E: 8.6x (consensus forward earnings)
– P/S (TTM): 6.7x
– EV/EBITDA (FY2025): ~11.5x (calculated: EV ~$11.9B / EBITDA ~$890M normalized)

Balance Sheet (FY2025)

Metric	Value	Assessment
**Cash & Short-term Investments**	$142.8M	Low absolute level
**Total Debt**	$2,142.6M	Significant leverage
**Net Debt**	$2,008.8M	Highly leveraged
**Debt-to-Equity**	991.2x	Extreme (due to negative tangible book)
**Current Ratio**	2.76x	Adequate
**Quick Ratio**	2.14x	Adequate
**Tangible Book Value**	-$1,513.0M	Negative (goodwill/intangibles-heavy)

Leverage Analysis: Halozyme carries substantial debt (primarily convertible notes and term loans) used to fund the Antares Pharma acquisition (2022) and share buybacks. The debt-to-equity ratio is distorted by negative tangible equity; however, operating cash flow of $677M provides ~3.2x interest coverage (interest expense ~$18M). The company generates strong FCF ($228M in FY2025) but has significant debt service obligations.

Cash Flow Statement (FY2025)

Metric	FY2023	FY2024	FY2025
**Operating Cash Flow**	~$450M	~$550M	$677.4M
**CapEx**	~$25M	~$30M	~$35M (est.)
**Free Cash Flow**	~$425M	~$520M	$228.1M*

FY2025 FCF impacted by one-time items; normalized FCF estimated at ~$550–600M.

Cash Flow Quality: Operating cash flow has grown consistently, tracking royalty revenue expansion. The company is cash-flow positive and self-funding operations, though FCF is partially diverted to debt service.

---

Risk & Catalyst Assessment (Next 12 Months)

Key Risks

Risk Factor	Description	Severity
**Partner Concentration**	>60% of royalties from Janssen/Roche; any disruption to DARZALEX SC or Phesgo supply/pricing would materially impact revenue	High
**Regulatory Delays**	Tecentriq SC US approval delay; potential FDA concerns on SC formulations	Medium
**Competition**	Emergence of alternative SC delivery technologies (e.g., Enable Injections, West Pharma)	Medium
**Debt Refinancing**	~$2.1B debt; rising rates could increase interest expense; refinancing risk in 2027–2028	Medium
**Patent Expiry**	Core ENHANZE patents beginning to expire late this decade; new IP needed	Long-term
**Payer Pressure**	Drug pricing reforms (IRA) could impact partner drug revenues and thus royalties	Medium

Catalysts

Catalyst	Expected Timing	Potential Impact
**Tecentriq SC US Approval**	2026–2027	Significant royalty upside
**Lilly Partnership Expansion**	2026–2027	Potential blockbuster SC GLP-1 formulation
**New Partnership Announcements**	Ongoing	Milestone fees + future royalties
**DARZALEX SC Label Expansion**	2026	Earlier-line multiple myeloma treatment
**Share Buyback Program**	Ongoing	EPS accretion
**Debt Refinancing**	2027	Lower interest expense

---

Competitive Landscape & Related Equities

Company	Ticker	Market Focus	Competitive Relationship
**Enable Injections**	Private	Wearable SC delivery devices	Competing technology for SC biologics
**West Pharmaceutical Services**	WST	Drug delivery systems	Competing/adjacent technology
**Biocon**	BIOCON.NS	Biosimilars	Potential competitor in SC biologics
**Lonza**	LONN.SW	CDMO	Manufacturing alternative

Frequently Co-Mentioned Equities:

Ticker	Relationship
**JNJ (Johnson & Johnson)**	Partner; DARZALEX SC is the largest royalty source for HALO
**RHHBY (Roche)**	Partner; multiple ENHANZE products (Phesgo, Ocrevus SC, Tecentriq SC)
**LLY (Eli Lilly)**	Partner; potential SC GLP-1 formulation could be transformative
**ARGX (argenx)**	Partner; VYVGART Hytrulo launched

---

Investment Thesis

Bull Case

• Royalty Growth Engine: DARZALEX SC and Phesgo continue to grow double-digits; Ocrevus SC and Tecentriq SC provide incremental upside. Revenue growth of 30%+ in FY2025 demonstrates momentum.
• Lilly Optionality: A subcutaneous formulation of tirzepatide (Mounjaro/Zepbound) via ENHANZE could be a multi-billion dollar royalty opportunity — potentially transformative.
• Asset-Light Model: 84% gross margins and 58% operating margins with minimal capex; high incremental margins on royalty growth.
• Attractive Valuation: Forward P/E of 8.6x appears inexpensive for a company growing revenue ~30% with expanding margins.

Bear Case

• Customer Concentration: Reliance on a handful of partners creates binary risk; any setback to DARZALEX SC or Phesgo would significantly impact revenue.
• Leverage Concerns: ~$2.1B debt with only $143M cash; negative tangible book value; refinancing risk if credit markets tighten.
• Patent Cliff: Core ENHANZE patents expire late this decade; without new IP, royalty rates could erode.
• Competitive Threat: Alternative SC delivery technologies could commoditize the platform.

---

Capital Raising Activity (Last 6 Months & Next 6 Months)

Period	Activity
**Last 6 Months (Feb–Aug 2026)**	No major equity or debt raises identified from provided data. Ongoing share buyback program (~$100–150M/quarter est.).
**Next 6 Months (Aug 2026–Feb 2027)**	Expect continued buybacks funded by operating cash flow. Potential refinancing of a portion of the ~$2.1B debt (maturities 2027–2029) — likely convertible notes or term loans. No equity issuance anticipated.

Share Count Trend: Diluted shares outstanding declined from 140.6M (FY2022) to 123.9M (FY2025) — a ~12% reduction through buybacks, providing meaningful EPS accretion.

---

Summary

Halozyme has successfully transformed from a development-stage enzyme company to a high-margin royalty aggregator with a best-in-class SC delivery platform. The combination of strong partner-driven growth, high incremental margins, and aggressive capital returns positions HALO as a compelling growth-at-a-reasonable-price (GARP) story. However, the high customer concentration and significant leverage warrant careful monitoring. The next 12–18 months will be pivotal as the company seeks to expand its partnership pipeline (particularly with Lilly) and manage its debt profile.

---

Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Data sourced from Yahoo Finance (as of August 07, 2026) and company filings; all estimates not explicitly sourced from the provided data are clearly labeled as such. The analysis may contain errors — always verify against primary filings (10-K/10-Q/8-K) before making any investment decision.